Skip to main content
logo
AbCellera Biologics Inc. (ABCL)
NASDAQ: ABCL · Real-Time Price · USD
3.280
+0.010 (0.31%)
At close: Mar 30, 2026, 4:00 PM EDT
3.280
0.00 (0.00%)
After-hours: Mar 30, 2026, 4:56 PM EDT

AbCellera Biologics Revenue

In the year 2025, AbCellera Biologics had annual revenue of $75.13M with 160.56% growth. AbCellera Biologics had revenue of $44.85M in the quarter ending December 31, 2025, with 788.18% growth.

Revenue (ttm)
$75.13M
Revenue Growth
+160.56%
P/S Ratio
13.13
Revenue / Employee
$133,680
Employees
562
Market Cap
994.37M

Revenue Chart

Revenue History

Fiscal Year EndRevenueChangeGrowth
Dec 31, 202575.13M46.30M160.56%
Dec 31, 202428.83M-9.19M-24.17%
Dec 31, 202338.03M-447.40M-92.17%
Dec 31, 2022485.42M110.22M29.38%
Dec 31, 2021375.20M142.05M60.92%
Dec 31, 2020 Pro Pro Pro
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company NameRevenue
Xeris Biopharma Holdings291.85M
Geron183.88M
CytomX Therapeutics76.20M
KalVista Pharmaceuticals73.62M
Septerna45.95M
EyePoint31.37M
Inventiva19.93M
uniQure16.10M
Revenue Rankings

ABCL News

More News